LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Predicting the risk of developing type 2 diabetes in Chinese people who have coronary heart disease and impaired glucose tolerance.

    Xu, Shishi / Scott, Charles A B / Coleman, Ruth L / Tuomilehto, Jaakko / Holman, Rury R

    Journal of diabetes

    2021  Volume 13, Issue 10, Page(s) 817–826

    Abstract: Aims: Robust diabetes risk estimates in Asian patients with impaired glucose tolerance (IGT) and coronary heart disease (CHD) are lacking. We developed a Chinese type 2 diabetes risk calculator using Acarbose Cardiovascular Evaluation (ACE) trial data.!# ...

    Abstract Aims: Robust diabetes risk estimates in Asian patients with impaired glucose tolerance (IGT) and coronary heart disease (CHD) are lacking. We developed a Chinese type 2 diabetes risk calculator using Acarbose Cardiovascular Evaluation (ACE) trial data.
    Methods: There were 3105 placebo-treated ACE participants with requisite data for model development. Clinically relevant variables, and those showing nominal univariate association with new-onset diabetes (P < .10), were entered into BASIC (clinical variables only), EXTENDED (clinical variables plus routinely available laboratory results), and FULL (all candidate variables) logistic regression models. External validation was performed using the Luzhou prospective cohort of 1088 Chinese patients with IGT.
    Results: Over median 5.0 years, 493 (15.9%) ACE participants developed diabetes. Lower age, higher body mass index, and use of corticosteroids or thiazide diuretics were associated with higher diabetes risk. C-statistics for the BASIC (using these variables), EXTENDED (adding male sex, fasting plasma glucose, 2-hour glucose, and HbA1c), and FULL models were 0.610, 0.757, and 0.761 respectively. The EXTENDED model predicted a lower 13.9% 5-year diabetes risk in the Luzhou cohort than observed (35.2%, 95% confidence interval 31.3%-39.5%, C-statistic 0.643).
    Conclusion: A risk prediction model using routinely available clinical variables can be used to estimate diabetes risk in Chinese people with CHD and IGT.
    MeSH term(s) Acarbose ; Adrenal Cortex Hormones/adverse effects ; Aged ; Algorithms ; Blood Glucose/analysis ; Body Mass Index ; China ; Coronary Disease/epidemiology ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/epidemiology ; Double-Blind Method ; Fasting ; Female ; Glucose Intolerance/epidemiology ; Glycated Hemoglobin A/analysis ; Humans ; Male ; Middle Aged ; Placebos ; Prospective Studies ; Reproducibility of Results ; Risk Factors ; Sodium Chloride Symporter Inhibitors/adverse effects
    Chemical Substances Adrenal Cortex Hormones ; Blood Glucose ; Glycated Hemoglobin A ; Placebos ; Sodium Chloride Symporter Inhibitors ; Acarbose (T58MSI464G)
    Language English
    Publishing date 2021-03-17
    Publishing country Australia
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 2503337-2
    ISSN 1753-0407 ; 1753-0393
    ISSN (online) 1753-0407
    ISSN 1753-0393
    DOI 10.1111/1753-0407.13175
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6791: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial.

    Gerstein, Hertzel C / Coleman, Ruth L / Scott, Charles A B / Xu, Shishi / Tuomilehto, Jaakko / Rydén, Lars / Holman, Rury R

    Diabetes care

    2020  Volume 43, Issue 9, Page(s) 2242–2247

    Abstract: Objective: We examined the impact of acarbose, an α-glucosidase inhibitor, on incident diabetes and regression to normoglycemia in 6,522 Acarbose Cardiovascular Evaluation (ACE) trial participants in China who had impaired glucose tolerance (IGT) and ... ...

    Abstract Objective: We examined the impact of acarbose, an α-glucosidase inhibitor, on incident diabetes and regression to normoglycemia in 6,522 Acarbose Cardiovascular Evaluation (ACE) trial participants in China who had impaired glucose tolerance (IGT) and coronary heart disease (CHD).
    Research design and methods: Participants were randomly assigned to acarbose or placebo and followed with four monthly fasting plasma glucose (FPG) tests and annual oral glucose tolerance tests. Incident diabetes was defined as two successive diagnostic FPG levels ≥7 mmol/L or 2-h plasma glucose (PG) levels ≥11.1 mmol/L while taking study medication or a masked adjudicated confirmation of this diagnosis. Regression to normoglycemia was defined as FPG <6.1 mmol/L and 2-h PG <7.8 mmol/L. Intention-to-treat and on-treatment analyses were conducted using Poisson regression models, overall and for subgroups (age, sex, CHD type, HbA
    Results: Incident diabetes was less frequent with acarbose compared with placebo (3.2 and 3.8 per 100 person-years, respectively; rate ratio 0.82 [95% CI 0.71, 0.94],
    Conclusions: Acarbose reduced the incidence of diabetes and promoted regression to normoglycemia in Chinese people with IGT and CHD.
    MeSH term(s) Acarbose/therapeutic use ; Aged ; Angiotensin Receptor Antagonists/therapeutic use ; Blood Glucose/analysis ; Blood Glucose/drug effects ; Blood Glucose/metabolism ; China/epidemiology ; Coronary Disease/blood ; Coronary Disease/complications ; Coronary Disease/drug therapy ; Coronary Disease/epidemiology ; Diabetes Mellitus/epidemiology ; Diabetes Mellitus/prevention & control ; Disease Progression ; Double-Blind Method ; Female ; Follow-Up Studies ; Glucose Intolerance/blood ; Glucose Intolerance/complications ; Glucose Intolerance/drug therapy ; Glucose Intolerance/epidemiology ; Glucose Tolerance Test ; Glycoside Hydrolase Inhibitors/therapeutic use ; Humans ; Incidence ; Male ; Middle Aged ; Prediabetic State/blood ; Prediabetic State/complications ; Prediabetic State/drug therapy ; Prediabetic State/epidemiology
    Chemical Substances Angiotensin Receptor Antagonists ; Blood Glucose ; Glycoside Hydrolase Inhibitors ; Acarbose (T58MSI464G)
    Language English
    Publishing date 2020-07-08
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 441231-x
    ISSN 1935-5548 ; 0149-5992
    ISSN (online) 1935-5548
    ISSN 0149-5992
    DOI 10.2337/dc19-2046
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1434: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 365: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.

    Wamil, Malgorzata / McMurray, John J V / Scott, Charles A B / Coleman, Ruth L / Sun, Yihong / Standl, Eberhard / Rydén, Lars / Holman, Rury R

    Diabetes research and clinical practice

    2020  Volume 170, Page(s) 108488

    Abstract: Aims: Heart failure is a fatal complication of type 2 diabetes but little is known about its incidence in people with impaired glucose tolerance (IGT). We used Acarbose Cardiovascular Evaluation (ACE) trial data to identify predictors of hospitalisation ...

    Abstract Aims: Heart failure is a fatal complication of type 2 diabetes but little is known about its incidence in people with impaired glucose tolerance (IGT). We used Acarbose Cardiovascular Evaluation (ACE) trial data to identify predictors of hospitalisation for heart failure (hHF) or cardiovascular (CV) death in patients with coronary heart disease (CHD) and IGT randomised to acarbose or placebo.
    Methods: Independent hHF/CV death risk factors were determined using Cox proportional hazards models, with participants censored at first hHF event, CV death, or end of follow-up.
    Results: During median 5-year follow-up, the composite outcome of hHF/CV death occurred in 393 (6.0%) participants. Significant hHF/CV death multivariate predictors were higher age and plasma creatinine, and prior heart failure (HF), myocardial infarction (MI), atrial fibrillation (AF) and stroke. Acarbose, compared with placebo, did not reduce hHF/CV death (hazard ratio [HR] 0.89, 95% CI 0.64-1.24, P = 0.48) or hHF (HR 0.90, 95% CI 0.74-1.10, P = 0.32).
    Conclusions: Patients with CHD and IGT at greater risk of hHF/CV death were older with higher plasma creatinine, prior HF, MI, AF or stroke. Addition of acarbose to optimised CV therapy to reduce post-prandial glucose excursions did not reduce the risk of hHF/CV death or hHF.
    Clinical trial registration: ClinicalTrials.gov, number NCT00829660, and the International Standard Randomised Controlled Trial Number registry, number ISRCTN91899513.
    MeSH term(s) Acarbose/therapeutic use ; Aged ; Coronary Disease/epidemiology ; Coronary Disease/mortality ; Creatinine/blood ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/drug therapy ; Double-Blind Method ; Female ; Glucose Intolerance/epidemiology ; Glycoside Hydrolase Inhibitors/therapeutic use ; Heart Failure/epidemiology ; Heart Failure/mortality ; Humans ; Incidence ; Male ; Middle Aged ; Myocardial Infarction/epidemiology ; Myocardial Infarction/mortality ; Proportional Hazards Models ; Risk Factors ; Treatment Outcome
    Chemical Substances Glycoside Hydrolase Inhibitors ; Creatinine (AYI8EX34EU) ; Acarbose (T58MSI464G)
    Language English
    Publishing date 2020-10-06
    Publishing country Ireland
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial
    ZDB-ID 632523-3
    ISSN 1872-8227 ; 0168-8227
    ISSN (online) 1872-8227
    ISSN 0168-8227
    DOI 10.1016/j.diabres.2020.108488
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2047: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes.

    Coleman, Ruth L / Scott, Charles A B / Lang, Zhihui / Bethel, M Angelyn / Tuomilehto, Jaakko / Holman, Rury R

    Cardiovascular diabetology

    2019  Volume 18, Issue 1, Page(s) 135

    Abstract: Background: Alpha-glucosidase inhibitors (AGIs) have been shown to reduce incident type 2 diabetes but their impact on cardiovascular (CV) disease remains controversial. We sought to identify the overall impact of AGIs with respect to incident type 2 ... ...

    Abstract Background: Alpha-glucosidase inhibitors (AGIs) have been shown to reduce incident type 2 diabetes but their impact on cardiovascular (CV) disease remains controversial. We sought to identify the overall impact of AGIs with respect to incident type 2 diabetes in individuals with impaired glucose tolerance (IGT), and CV outcomes in those with IGT or type 2 diabetes.
    Methods: We used PubMed and SCOPUS to identify randomized controlled trials reporting the incidence of type 2 diabetes and/or CV outcomes that had compared AGIs with placebo in populations with IGT or type 2 diabetes, with or without established CV disease. Eligible studies were required to have ≥ 500 participants and/or ≥ 100 endpoints of interest. Meta-analyses of available trial data were performed using random effects models to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for incident type 2 diabetes and CV outcomes.
    Results: Of ten trials identified, three met our inclusion criteria for incident type 2 diabetes and four were eligible for CV outcomes. The overall HR (95% CI) comparing AGI with placebo for incident type 2 diabetes was 0.77 (0.67-0.88), p < 0.0001, and for CV outcomes was 0.98 (0.89-1.10), p = 0.85. There was little to no heterogeneity between studies, with I
    Conclusions: Allocation of people with IGT to an AGI significantly reduced their risk of incident type 2 diabetes by 23%, whereas in those with IGT or type 2 diabetes the impact on CV outcomes was neutral.
    MeSH term(s) Aged ; Cardiovascular Diseases/diagnosis ; Cardiovascular Diseases/mortality ; Cardiovascular Diseases/prevention & control ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/mortality ; Female ; Glucose Intolerance/diagnosis ; Glucose Intolerance/drug therapy ; Glucose Intolerance/mortality ; Glycoside Hydrolase Inhibitors/adverse effects ; Glycoside Hydrolase Inhibitors/therapeutic use ; Humans ; Incidence ; Male ; Middle Aged ; Randomized Controlled Trials as Topic ; Risk Assessment ; Risk Factors ; Treatment Outcome
    Chemical Substances Glycoside Hydrolase Inhibitors
    Language English
    Publishing date 2019-10-17
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't ; Review
    ISSN 1475-2840
    ISSN (online) 1475-2840
    DOI 10.1186/s12933-019-0933-y
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial.

    Othonos, Nantia / Pofi, Riccardo / Arvaniti, Anastasia / White, Sarah / Bonaventura, Ilaria / Nikolaou, Nikolaos / Moolla, Ahmad / Marjot, Thomas / Stimson, Roland H / van Beek, André P / van Faassen, Martijn / Isidori, Andrea M / Bateman, Elizabeth / Sadler, Ross / Karpe, Fredrik / Stewart, Paul M / Webster, Craig / Duffy, Joanne / Eastell, Richard /
    Gossiel, Fatma / Cornfield, Thomas / Hodson, Leanne / Jane Escott, K / Whittaker, Andrew / Kirik, Ufuk / Coleman, Ruth L / Scott, Charles A B / Milton, Joanne E / Agbaje, Olorunsola / Holman, Rury R / Tomlinson, Jeremy W

    Nature communications

    2023  Volume 14, Issue 1, Page(s) 1025

    Abstract: Glucocorticoids prescribed to limit inflammation, have significant adverse effects. As 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) regenerates active glucocorticoid, we investigated whether 11β-HSD1 inhibition with AZD4017 could mitigate adverse ... ...

    Abstract Glucocorticoids prescribed to limit inflammation, have significant adverse effects. As 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) regenerates active glucocorticoid, we investigated whether 11β-HSD1 inhibition with AZD4017 could mitigate adverse glucocorticoid effects without compromising their anti-inflammatory actions. We conducted a proof-of-concept, randomized, double-blind, placebo-controlled study at Research Unit, Churchill Hospital, Oxford, UK (NCT03111810). 32 healthy male volunteers were randomized to AZD4017 or placebo, alongside prednisolone treatment. Although the primary endpoint of the study (change in glucose disposal during a two-step hyperinsulinemic, normoglycemic clamp) wasn't met, hepatic insulin sensitivity worsened in the placebo-treated but not in the AZD4017-treated group. Protective effects of AZD4017 on markers of lipid metabolism and bone turnover were observed. Night-time blood pressure was higher in the placebo-treated but not in the AZD4017-treated group. Urinary (5aTHF+THF)/THE ratio was lower in the AZD4017-treated but remained the same in the placebo-treated group. Most anti-inflammatory actions of prednisolone persisted with AZD4017 co-treatment. Four adverse events were reported with AZD4017 and no serious adverse events. Here we show that co-administration of AZD4017 with prednisolone in men is a potential strategy to limit adverse glucocorticoid effects.
    MeSH term(s) Humans ; Male ; 11-beta-Hydroxysteroid Dehydrogenase Type 1/antagonists & inhibitors ; Anti-Inflammatory Agents/adverse effects ; Glucocorticoids/adverse effects ; Inflammation/drug therapy ; Prednisolone/adverse effects
    Chemical Substances 11-beta-Hydroxysteroid Dehydrogenase Type 1 (EC 1.1.1.146) ; Anti-Inflammatory Agents ; Glucocorticoids ; Prednisolone (9PHQ9Y1OLM) ; 2-(1-(5-(cyclohexylcarbamoyl)-6-propylsulfanylpyridin-2-yl)-3-piperidyl)acetic acid
    Language English
    Publishing date 2023-02-23
    Publishing country England
    Document type Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2553671-0
    ISSN 2041-1723 ; 2041-1723
    ISSN (online) 2041-1723
    ISSN 2041-1723
    DOI 10.1038/s41467-023-36541-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top